These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7691988)

  • 21. Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.
    Whang Y; Silberklang M; Morgan A; Munshi S; Lenny AB; Ellis RW; Kieff E
    J Virol; 1987 Jun; 61(6):1796-807. PubMed ID: 3033311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells.
    Hedrick JA; Lao Z; Lipps SG; Wang Y; Todd SC; Lambris JD; Tsoukas CD
    J Immunol; 1994 Nov; 153(10):4418-26. PubMed ID: 7963519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
    Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
    Front Immunol; 2018; 9():932. PubMed ID: 29765376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.
    Sashihara J; Burbelo PD; Savoldo B; Pierson TC; Cohen JI
    Virology; 2009 Sep; 391(2):249-56. PubMed ID: 19584018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
    Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
    Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
    [No Abstract]   [Full Text] [Related]  

  • 26. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells.
    Rowe M; Evans HS; Young LS; Hennessy K; Kieff E; Rickinson AB
    J Gen Virol; 1987 Jun; 68 ( Pt 6)():1575-86. PubMed ID: 2438376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temperature dependent characteristics of a recombinant infectious hematopoietic necrosis virus glycoprotein produced in insect cells.
    Cain KD; Byrne KM; Brassfield AL; LaPatra SE; Ristow SS
    Dis Aquat Organ; 1999 Apr; 36(1):1-10. PubMed ID: 10349547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.
    Thorley-Lawson DA; Geilinger K
    Proc Natl Acad Sci U S A; 1980 Sep; 77(9):5307-11. PubMed ID: 6254073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus gp350-specific antibody titers and antibody-dependent cellular cytotoxic effector function in different groups of patients: a study using cloned gp350-expressing transfected human T cell targets.
    Khyatti M; Stefanescu I; Blagdon M; Menezes J
    J Infect Dis; 1994 Dec; 170(6):1439-47. PubMed ID: 7995983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular synthesis of Epstein-Barr virus membrane antigen gp350/220. Inhibitory effect of monensin on its expression.
    Bertoni G; Nguyen QV; Humphreys RE; Sairenji T
    Intervirology; 1989; 30(2):61-73. PubMed ID: 2542183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.
    Tanner J; Whang Y; Sample J; Sears A; Kieff E
    J Virol; 1988 Dec; 62(12):4452-64. PubMed ID: 2460635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure of the Epstein-Barr virus major envelope glycoprotein.
    Szakonyi G; Klein MG; Hannan JP; Young KA; Ma RZ; Asokan R; Holers VM; Chen XS
    Nat Struct Mol Biol; 2006 Nov; 13(11):996-1001. PubMed ID: 17072314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli.
    Lounsbach GR; Bourgeois C; West WH; Robinson JW; Carter MJ; Toms GL
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2559-65. PubMed ID: 7506297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human herpesvirus-6 glycoprotein H and L homologs are components of the gp100 complex and the gH external domain is the target for neutralizing monoclonal antibodies.
    Liu DX; Gompels UA; Foa-Tomasi L; Campadelli-Fiume G
    Virology; 1993 Nov; 197(1):12-22. PubMed ID: 7692666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic peptides to identify antigenic determinants on Epstein-Barr virus gp350/220.
    Bertoni G; Kostyal DA; Reisert PS; Humphreys RE; Sairenji T
    Intervirology; 1990; 31(5):290-4. PubMed ID: 1703134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody.
    Maunders MJ; Petti L; Rowe M
    J Gen Virol; 1994 Apr; 75 ( Pt 4)():769-78. PubMed ID: 7512118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge.
    Emini EA; Schleif WA; Silberklang M; Lehman D; Ellis RW
    J Med Virol; 1989 Feb; 27(2):120-3. PubMed ID: 2537882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera.
    Pither RJ; Nolan L; Tarlton J; Walford J; Morgan AJ
    J Gen Virol; 1992 Jun; 73 ( Pt 6)():1409-15. PubMed ID: 1376768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the upregulation of the TNF-alpha gene expression in monocytic cells via NF-kappaB involving PKC, PI3-K and tyrosine kinases.
    D'Addario M; Ahmad A; Morgan A; Menezes J
    J Mol Biol; 2000 May; 298(5):765-78. PubMed ID: 10801347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B.
    Orvell C; Norrby E; Mufson MA
    J Gen Virol; 1987 Dec; 68 ( Pt 12)():3125-35. PubMed ID: 2447224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.